Wednesday turned out to be a pretty good news day for two of the COVID-19 vaccines, one that's already out in mass production and another that's trying to get full FDA emergency approval.

WOODTV reports on Wednesday that the Johnson & Johnson's shot for the COVID-19 vaccine reciveved promising news from the Fedreal Drug Administration as they said according to WOODTV,

the single-dose shot is about 66% effective at preventing moderate to severe COVID-19. That efficacy rate is even higher, 85%, against the most serious illness.

Even more promising about the Johnson & Johnson shot is that 28 days after recieving the single dose vaccine, there were no deathes or hospitalizations reported by people who had recieved the shot.

Kent County Health Department Immunization Supervisor Mary Wisinski told WOODTV,

“A better thing to look at is how effective these vaccines are at reducing severe disease, hospitalizations and even deaths. When you look at those safety profiles, all three of these vaccines are equally as effective,” Wisinski said. “So, I don’t want people to get the idea that the Johnson & Johnson vaccine is less than the other two because it’s absolutely not.”

Johnson & Johnson getting emergency FDA approval would make them the thrid vaccine avaliable in the United States for COVID-19, and would be the only vaccine that requires one dose.  It's also an easier vaccine to roll-out in a massive rollout because the J&J vaccine doesn't require special cold storage or the hope that the clinics have enough doses for everyone to get a second dose that's required for the Pfizer and Moderna vaccines.

WOODTV says the FDA will meet Friday to discuss the emergency authorization for the Johnson & Johnson vaccine.

50 Famous Brands That No Longer Exist